Stay updated on HMPL-689 Safety & PK in Lymphomas Clinical Trial
Sign up to get notified when there's something new on the HMPL-689 Safety & PK in Lymphomas Clinical Trial page.

Latest updates to the HMPL-689 Safety & PK in Lymphomas Clinical Trial page
- Check5 days agoChange DetectedThe clinical development of HMPL-689 has been halted by HUTCHMED, and several key dates related to results reporting have been updated. Additionally, detailed information regarding adverse events and pharmacokinetic parameters has been added, enhancing the understanding of the drug's safety and efficacy.SummaryDifference85%
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check48 days agoChange DetectedThe page now indicates that results have been submitted, replacing the previous message that no results were posted.SummaryDifference0.1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
Stay in the know with updates to HMPL-689 Safety & PK in Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HMPL-689 Safety & PK in Lymphomas Clinical Trial page.